Humanigen, Inc.

HGEN

US4448632038

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:14:16 2024-07-12 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.50%		-50.00%	-91.67%

May. 01	Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	CI
Apr. 12	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI

HUMANIGEN, INC : Other Events, Financial Statements and Exhibits (form 8-K)

January 29, 2021 at 07:32 am EST

Item 8.01. Other Events.

On January 29, 2021, Humanigen, Inc. (the "Company") announced that it had completed enrollment for its pivotal phase 3 study of lenzilumabTMfor COVID-19. A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits






 (d) Exhibits

Exhibit No. Exhibit Description

99.1 Press release, dated January 29, 2021

Latest news about Humanigen, Inc.

Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	May. 01	CI
Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	Apr. 12	CI
Final DIP Financing Approved for Humanigen, Inc.	Mar. 07	CI
Motion for Asset Sale Approved for Humanigen, Inc.	Feb. 16	CI
Notice for Auction Cancellation Filed by Humanigen, Inc.	Feb. 12	CI
Bidding Procedure Approved for Humanigen, Inc.	Jan. 24	CI
19 treatment developer Humanigen files for Chapter 11 bankruptcy	Jan. 04	RE
Motion for Asset Sale Filed by Humanigen, Inc.	Jan. 03	CI
Humanigen, Inc. Filed for Bankruptcy	Jan. 03	CI
Interim DIP Financing Approved for Humanigen, Inc.	Jan. 02	CI
Xspray Pharma Names Chief Commercial Officer	23-09-15	MT
Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer	23-09-14	CI
North American Morning Briefing : PCE Inflation -2-	23-08-31	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index	23-07-28	CI
Sector Update: Health Care Stocks Steady in Late Afternoon Trading	23-07-25	MT
Sector Update: Health Care Stocks Steady Tuesday Afternoon	23-07-25	MT
Sector Update: Health Care	23-07-25	MT
Humanigen Issues 'Going Concern' Warning; Shares Hit 52-Week Low	23-07-25	MT
Humanigen, Inc. Announces Board Changes	23-07-25	CI
Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index	23-07-25	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Value Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell 3000E Value Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Growth Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Index	23-06-23	CI

Chart Humanigen, Inc.

Duration

Period

More charts

Company Profile

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUMANIGEN, INC.	-91.67%	119
CSL LIMITED	+7.94%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.18B
BIOGEN INC.	-13.04%	32.26B
UCB	+80.80%	29.79B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.06B
INCYTE CORPORATION	+1.93%	14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.01B
ALTEOGEN INC.	+177.16%	10.71B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.89B